Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4- dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: Potential relevance to the pathogenesis of Parkinson's disease

Journal of Neurochemistry

Volumn 71, Issue 5, 1998, Pages 2049-2062

  Li, Hong ^a   Shen, Xue Ming ^a   Dryhurst, Glenn ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

5 S Cysteinyldopamine; Complex I; Cysteine; DHBT 1; Mitochondria; Parkinson's disease

Indexed keywords

BENZOTHIAZINE DERIVATIVE; CYSTEINYLDOPA; GLUTATHIONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

ARTICLE; BRAIN MITOCHONDRION; DOPAMINERGIC NERVE CELL; DRUG OXIDATION; ENZYME ACTIVITY; GLUTATHIONE METABOLISM; HUMAN; MITOCHONDRIAL RESPIRATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 0031755115     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.71052049.x     Document Type: Article

References (66)

1. Alam Z. I., Daniel S. E., Lees A. J., Marsden C. D., Jenner P., and Halliwell B. (1997) A generalised increase in protein carbonyls in the brain in Parkinson's disease but not incidental Lewy body disease. J. Neurochem. 69, 1326-1329.
2. Bannai S. (1984) Transport of cystine and cysteine in mammalian cells. Biochim. Biophys. Acta 779, 289-306.
3. Ben-Shachar D., Riederer P., and Youdim M. B. H. (1991) Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 57, 1609-1614.
4. Bonifati M. G., Vanacore N., and Fabrizio E. (1994) Parkinsonism after exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate). Scand. J. Work Environ. Health 20, 301-305.
5. Clark J. M. and Switzer R. L. (1977) Experimental Biochemistry, 2nd edit., p. 12. W. H. Freeman and Company, New York.
6. Dexter D. T., Carayon A., Vidailhet M., Ruberg M., Agid F., Agid Y., Lees A., Wells F. R., and Marsden C. D. (1990) Decreased ferritin levels in brain in Parkinson's disease. J. Neurochem. 55, 16-20.
7. Dexter D. T., Sian J., Rose S., Hindmarsh J.-G., Mann V.M., Cooper J. M., Wells F. R., Daniel S. E., Lees A. J., Schapira A. H. V., Jenner P., and Marsden C. D. (1994) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35, 38-44.
8. Dryhurst G. (1998) Glutathione, cysteine, and the neuromelanin pathway: potential roles in the pathogenesis of Parkinson's disease - a new hypothesis, in Glutathione in the Nervous System (Shaw C. A., ed), pp. 305-342. Taylor and Francis, Washington, D.C.
9. Fearnely J. M. and Lees A. J. (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114, 2283-2301.
10. Fornstedt B., Brun A., Rosengren E., and Carlsson A. (1989) The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J. Neural Transm. Park. Dis. Dement. Sect. 1, 279-295.
11. Golbe L. I., Farrell T. M., and Davis P. H. (1990) Follow-up study of early life protective and risk factors in PD. Mov. Disord. 5, 66-70.
12. Gorell J. M., Johnson C. C., Rybicki B. A., Peterson E. L., Kortsha G. X., Brown G. G., and Richardson R. J. (1997) Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 48, 650-658.
13. Graham D. G. (1978) Oxidation pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633-643.
14. Gutman M., Mersmann H., Luthy J., and Singer T. P. (1970) Action of sulfhydryl inhibitors on different forms of the respiratory chain-linked reduced nicotinamide-adenine dinucleotide dehydrogenase. Biochemistry 9, 2678-2687.
15. Haas R. H., Nasirian F., Nakano K., Ward D., Pay M., Hill R., and Shults C. W. (1995) Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann. Neurol. 37, 714-722.
16. Hertzman D., Wiens M., Bowering D., Snow B., and Calne D. (1990) Parkinson's disease: a case control study of occupational environmental risk factors. Am. J. Ind. Med. 17, 349-355.
17. Ikebe S., Tanaka M., and Ozawa T. (1995) Point mutations of mitochondrial genome in Parkinson's disease. Nature 334, 345-348.
18. Jain A., Mårtensson J., Stole E., Auld P. A. M., and Meister A. (1991) Glutathione deficiency leads to mitochondrial damage in brain. Proc. Natl. Acad. Sci. USA 88, 1913-1917.
19. Jellinger K., Kienzl E., Rumpelmair G., Riederer P., Stachelberger H., Ben-Shachar D., and Youdim M. B. H. (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J. Neurochem. 59, 1168-1171.
20. Jenner P. (1993) Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol. Scand. 87, 6-13.
21. Jenner P. and Olanow C. W. (1996) Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders, in Neurodegeneration and Neuroprotection in Parkinson's Disease (Olanow C. W., Jenner P., and Youdim M., eds), pp. 23-45. Academic Press, San Diego.
22. Jenner P., Dexter D. T., Sian J., Schapira A. H. V., and Marsden C. D. (1992a) Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann. Neurol. 32, S82-S87.
23. Jenner P., Schapira A. H. V., and Marsden C. D. (1992b) New insights into the cause of Parkinson's disease. Neurology 42, 2241-2250.
24. Johnson W. G., Hodge S. E., and Duvoisin R. (1990) Twin studies and the genetics of Parkinson's disease - a reappraisal. Mov. Disord. 5, 187-194.
25. Koller W., Vetere-Overfield B., Gray C., Alexander C., Chin T., Dolezal J., Hassanein R., and Tanner C. (1990) Environmental risk factors in Parkinson's disease. Neurology 40, 1218-1221.
26. Kosel S., Egensperger R., von Eitzen U., Mahraein P., and Groeber M. B. (1997) On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol. 93, 105-108.
27. Krige D., Carroll M. T., Cooper J. M., Marsden C. D., and Schapira A. H. (1992) Platelet mitochondrial function in Parkinson's disease. Ann. Neurol. 32, 782-788.
28. Li H. and Dryhurst G. (1997) Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1): a putative nigral endotoxin of relevance to Parkinson's disease. J. Neurochem. 69, 1530-1541.
29. Macho A., Hirsch T., Marzo I., Marchetti P., Dallaporta B., Susin S. A., Zamzami N., and Kroemer G. (1997) Glutathione depletion is an early and calcium elevation is a late event of thymocyte apoptosis. J. Immunol. 158, 4612-4619.
30. Mann V. M., Cooper J. M., Krige D., Daniel S. E., Schapira A. H. V., and Marsden C. D. (1992) Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115, 333-342.
31. Maraganore D.M., Harding A. E., and Marsden C. D. (1991) A clinical and genetic study of familial Parkinson's disease. Mov. Disord. 6, 205-211.
32. Mårtensson J., Lai J. C. K., and Meister A. (1990) A high affinity transport of glutathione is part of a multicomponent system essential for mitochondrial function. Proc. Natl. Acad. Sci. USA 87, 7185-7189.
33. Meister A. and Anderson M. E. (1983) Glutathione. Annu. Rev. Biochem. 52, 711-760.
34. Meister A., Tate S. S., and Griffith O. W. (1981) γ-Glutamyl transpeptidase. Methods Enzymol. 77, 237-253.
35. Mizuno Y., Matuda S., Yoshino H., Mori H., Hattori N., and Ikebe S. (1994) An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann. Neurol. 35, 204-210.
36. Mochizuki H., Goto K., Mori H., and Mizuno Y. (1996) Histochemical detection of apoptosis in Parkinson's disease. J. Neurol. Sci. 137, 120-123.
37. Parker W. D., Boyson S. J., and Parks J. K. (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26, 719-723.
38. Pearce R. K. B., Owen A., Daniel S., Jenner P., and Marsden C. D. (1997) Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural Transm. 104, 661-677.
39. Rajput A. H., Uitti R. J., Stern W., Laverty W., O'Donnell K., O'Donnell D., Yuen W. K., and Dua A. (1987) Drinking water, pesticides and herbicides and the etiology of Parkinson's disease. Can. J. Neurol. Sci. 14, 414-418.
40. Riederer P., Sofic E., Rausch W.-D., Schmidt B., Reynolds G. P., Jellinger K., and Youdim M. B. H. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520.
41. Ross H. R., Romrell L. J., and Kaye G. I. (1995) Histology. A Text and Atlas, chapter 11, p. 282. Williams and Wilkins, Baltimore.
42. Rybicki B. A., Johnson C. C., Uman J., and Gorell J. M. (1993) Parkinson's disease mortality and the industrial use of heavy metals in Michigan. Mov. Disord. 8, 87-92.
43. Schapira A. H. V. (1996) Mitochondrial dysfunction in neurodegeneration: prospects for neuroprotection, in Neurodegeneration and Neuroprotection in Parkinson's Disease (Olanow C. W., Jenner P., and Youdim M., eds), pp. 103-124. Academic Press, San Diego.
44. Schapira A. H. V., Cooper J. M., Dexter D., Clark J. B., Jenner P., and Marsden C. D. (1990a) Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54, 823-827.
45. 1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 55, 2142-2145.
46. Seaton T. A., Jenner P., and Marsden C. D. (1996) Mitochondrial respiratory enzyme function and superoxide dismutase activity following brain glutathione depletion in rat. Biochem. Pharmacol. 52, 1657-1663.
47. Semchuk K. M., Love E. J., and Lee R. G. (1992) Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 42, 1328-1335.
48. Shan X., Finkelstein M., Jones D.P., and Anders M.W. (1993) Experimental manipulation of mitochondrial glutathione concentrations, in Mitochondrial Dysfunction, Methods in Toxicology. Vol. 2 (Lash L. H. and Jones D. P., eds), pp. 227-234. Academic Press, London.
49. Sheehan J. P., Swerdlow R. H., Parker W. D., Miller S. W., Davis R. E., and Tuttle J. B. (1997) Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease. J. Neurochem. 68, 1221-1233.
50. Shen X.-M. and Dryhurst G. (1996) Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease. Chem. Res. Toxicol. 9, 751-763.
51. Shen X.-M. and Dryhurst G. (1998) Iron-and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: possible insights into iron-and manganese-mediated dopaminergic neurotoxicity. Chem. Res. Toxicol. 11, 824-837.
52. Shen X.-M., Zhang F., and Dryhurst G. (1997) Oxidation of dopamine in the presence of cysteine: characterization of new toxic products. Chem. Res. Toxicol. 10, 147-155.
53. Sian J., Dexter D., Lees A., Daniel S., Agid Y., Javoy-Agid F., Jenner P., and Marsden C. D. (1994a) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting the basal ganglia. Ann. Neurol. 36, 348-355.
54. Sian J., Dexter D. T., Lees A. J., Daniel S., Jenner P., and Marsden C. D. (1994b) Glutathione-related enzymes in brain in Parkinson's disease. Ann. Neurol. 36, 356-361.
55. Slivka A., Mytilineou C., and Cohen G. (1987) Histochemical evaluation of glutathione in brain. Brain Res. 409, 275-284.
56. Sofic E., Riederer P., Heisen H., Bechmann H., Reynolds G. P., Habenstreit G., and Youdim M. B. H. (1988) Increases of iron (III) and total iron in postmortem substantia nigra in parkinsonian brains. J. Neural Transm. 74, 199-205.
57. Sofic E., Lange K. W., Jellinger K., and Riederer P. (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142, 128-130.
58. Steventon G. B., Heafield M. T. E., Waring R. H., and Williams A.C. (1989) Xenobiotic metabolism in Parkinson's disease. Neurology 39, 883-887.
59. Swerdlow R. H., Parks J. K., Miller S. W., Tuttle J. B., Trimmer P. A., Sheehan J. P., Bennet J. R., Davis R. E., and Parker W. D. (1996) Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40, 663-671.
60. Tanner C. M., Chen B., Wang W., Peng M., Liu Z., Liang X., Kao L.-C., Gilley D. W., Goetz C. G., and Schoenberg B. S. (1989) Environmental factors and Parkinson's disease. Neurology 39, 660-664.
61. Toffa S., Kunikowska G. M., Zeng B.-Y., Jenner P., and Marsden C. D. (1997) Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. J. Neural Transm. 104, 67-75.
62. Wang J. D., Huang C. C., Hwang Y. H., Chiang J. R., Lin J. M., and Chen J. S. (1989) Manganese-induced parkinsonism: an outbreak due to an unrepaired ventilation control system in a ferromanganese smelter. Br. J. Ind. Med. 46, 856-859.
63. Wooten G. F., Currie L., Bennett J. P., Harrison M. B., Trugman J. M., and Parker J. W. D. (1997) Maternal inheritance in Parkinson's disease. Ann. Neurol. 41, 265-268.
64. Zhang F. and Dryhurst G. (1994) Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. J. Med. Chem. 37, 1084-1098.
65. Zhang F. and Dryhurst G. (1995) Reactions of cysteine and cysteine derivatives with dopamine-o-quinone and further insights into the oxidation chemistry of 5-S-cysteinyldopamine: potential insights into idiopathic Parkinson's disease. Bioorg. Chem. 23, 193-216.
66. Zhang Y., Marcillat O., Giulivi C., Ernsters L., and Davies K. J. A. (1990) The oxidative inactivation of mitochondrial electron transport chain components and ATPase. J. Biol. Chem. 16330-16336.